Literature DB >> 22641282

Treatment of myelodysplastic syndromes: practical tools for effective management.

Sandra E Kurtin1, Erin P Demakos, Janet Hayden, Claudia Boglione.   

Abstract

Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid malignancies with variability in clinical presentation, disease trajectory, treatment goals, and expected outcomes. The treatment of patients with MDS, therefore, often differs from patient to patient. Tools are needed to aid effective communication with patients, their caregivers, and their dedicated team of healthcare professionals. The use of methods often employed in clinical trials can help healthcare providers diagnose and classify risk status, track trends within patient responses, manage adverse events, set treatment expectations, and provide ongoing supportive care. This article discusses several tools and strategies available for the management of patients with MDS throughout the continuum of their disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22641282     DOI: 10.1188/12.CJON.S1.23-35

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


  2 in total

Review 1.  Myeloid toxicity of cancer treatment.

Authors:  Sandra Kurtin
Journal:  J Adv Pract Oncol       Date:  2012-07

Review 2.  Practical Strategies for Management of Lenalidomide-Associated Cytopenias in Myelodysplastic Syndromes With del(5q).

Authors:  Sandra E Kurtin; Jean A Ridgeway; Sara Tinsley
Journal:  J Adv Pract Oncol       Date:  2017-11-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.